Global Orphan Drugs Market by Disease Type (Oncologic Diseases, Metabolic Diseases, Hematologic and Immunologic Diseases, Infectious Diseases, Neurologic Diseases and Other Rare Diseases), Indication (Non-Hodgkin Lymphoma, Acute Myeloid Leukemia, Cystic Fibrosis, Glioma, Pancreatic Cancer, Ovarian Cancer, Multiple Myeloma, Duchenne Muscular Dystrophy, Graft vs Host Disease, Renal Cell Carcinoma and Others) - Global Opportunity Analysis and Industry Forecast, 2014-2022

Global Orphan Drugs Market by Disease Type (Oncologic Diseases, Metabolic Diseases, Hematologic and Immunologic Diseases, Infectious Diseases, Neurolo

Category : Pharmaceuticals
Published On : April  2017
Pages : 140



TOLL FREE
+1-971-202-1575
------------ Or -------------
help@researchbeam.com

The pharmaceutical agents that are administered to treat, diagnose, and prevent life-threatening diseases (rare diseases) are known as orphan drugs. The global orphan drugs market accounted for $106 billion in 2015, and is anticipated to reach $169 billion by 2022, registering a CAGR of 6.8% from 2016 to 2022.

Orphan drugs are used to treat rare (orphaned) diseases prevalent in a very small patient pool. Hence, the pharmaceutical industry takes little interest in their development. Moreover, their development requires high cost and the chances of returns on investment are comparatively less when compared to non-orphan drugs. These drugs treat different rare diseases, such as non-Hodgkin lymphoma, acute myeloid leukemia, cystic fibrosis, and others.

Conducive government regulations and market exclusivity for orphan drugs drives the global orphan drugs market. In addition, surge in prevalence of rare diseases and rise in investment in research, drug development, and innovation supplement the market growth. However, limited patient pool for clinical trials & product marketing and high treatment costs per patient impede the market growth. Furthermore, growth in novel indications for known orphan drugs and untapped emerging markets offer lucrative opportunities for the market players.

The orphan drugs market is segmented based on disease type, indication, and geography. Based on disease type, the market is divided into oncologic diseases, metabolic diseases, hematologic and immunologic diseases, infectious diseases, neurologic diseases, and other rare diseases. In the orphan drugs disease type segment, oncologic diseases occupied dominant share in 2015, and the segment is expected to maintain this trend during the forecast period. This is attributed to the array of different forms of rare cancers, such as leukemia, myeloma, angiosarcoma, and others prevalent in the patient population.

Based on indication, this market is classified into non-Hodgkin lymphoma, acute myeloid leukemia, cystic fibrosis, glioma, pancreatic cancer, ovarian cancer, multiple myeloma, Duchenne muscular dystrophy, Graft vs host disease, renal cell carcinoma, and others. The non-Hodgkin lymphoma was the highest revenue contributor in 2015, while renal cell carcinoma is anticipated to grow at the highest rate. The growth for this segment is due to increase in investment in R&D throughout the world along with surge in awareness about kidney cancer.

Geographically, this market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. North America accounted for the largest market share in the orphan drugs market in 2015, and is expected to retain its dominance throughout the forecast period. This is primarily attributed to the higher buying power, availability, accessibility, and treatment options that favor the utilization of orphan drugs in this region. There is also an increase in product approvals for different pharmaceutical products designated as orphan drugs by the U.S. Food and Drug Administration (FDA), which fosters the market growth. However, Asia-Pacific is expected to emerge as a lucrative area with maximum growth potential, owing to the improvement in R&D facilities, available disposable income, and rapidly developing economic conditions.

Product development is the key strategy adopted by market players. The report provides a comprehensive analysis of the key players that operate in the global orphan drugs market.

KEY PLAYERS PROFILED

  • AbbVie Inc.
  • Aegerion Pharmaceuticals, Inc.
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • F. Hoffmann-La Roche Ltd.  
  • GlaxoSmithKline plc
  • Johnson & Johnson.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi

KEY MARKET BENEFITS

  • The study provides an in-depth analysis of the global orphan drugs market along with the current trends and future estimations to elucidate the imminent investment pockets.
  • The report presents quantitative analysis of the market from 2014 to 2022 to enable stakeholders to capitalize on the prevailing market opportunities.
  • Extensive analysis of the market based on indications assists in understanding the trends in the industry.
  • Key market players along with their strategies are thoroughly analyzed to understand the competitive outlook of the industry.

KEY MARKET SEGMENTS

By Disease Type

  • Oncologic Diseases
  • Metabolic Diseases
  • Hematologic and Immunologic Diseases
  • Infectious Diseases
  • Neurologic Diseases
  • Other Rare Diseases

By Indication

  • Non-Hodgkin Lymphoma
  • Acute Myeloid Leukemia
  • Cystic Fibrosis
  • Glioma
  • Pancreatic Cancer
  • Ovarian Cancer
  • Multiple Myeloma
  • Duchenne Muscular Dystrophy
  • Graft vs Host Disease
  • Renal Cell Carcinoma
  • Others

By Geography

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • India
    • South Korea
    • Taiwan
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Turkey
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Other players in the value chain include (profiles not included in the report)

  • Bayer HealthCare Pharmaceuticals Inc
  • Vertex Pharmaceuticals
  • Merck & Co., Inc.,
  • Alexion Pharmaceuticals, Inc.
  • Boehringer Ingelheim GmbH
  • Amgen Inc.
  • Biogen Idec
  • Actelion Pharmaceuticals Ltd
  • AstraZeneca plc
  • Janssen Biotech, Inc.

CHAPTER 1 INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY

1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models

CHAPTER 2 EXECUTIVE SUMMARY

2.1. CXO PERSPECTIVE

CHAPTER 3 MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS

3.2.1. Top investment pockets
3.2.2. Top winning strategies

3.3. PORTERS FIVE FORCES ANALYSIS
3.4. PATENT ANALYSIS

3.4.1. Patent analysis by year
3.4.2. Patent analysis by region
3.4.3. Patent analysis by indication

3.5. REGULATIONS
3.6. MARKET DYNAMICS

3.6.1. Drivers

3.6.1.1. Conducive government legislations
3.6.1.2. Market exclusivity for orphan drugs
3.6.1.3. Surge in prevalence of rare diseases

3.6.2. Restraints

3.6.2.1. Limited patient pool for clinical trial and product marketing
3.6.2.2. High treatment costs per patient

3.6.3. Opportunities

3.6.3.1. Growing novel indications designated for known orphan drugs
3.6.3.2. Untapped emerging markets

CHAPTER 4 ORPHAN DRUGS MARKET, BY DISEASE TYPE

4.1. OVERVIEW

4.1.1. Market size and forecast

4.2. ONCOLOGIC DISEASES

4.2.1. Key market trends
4.2.2. Growth factors and opportunities
4.2.3. Market size and forecast

4.3. METABOLIC DISEASES

4.3.1. Key market trends
4.3.2. Growth factors and opportunities
4.3.3. Market size and forecast

4.4. HEMATOLOGIC AND IMMUNOLOGIC DISEASES

4.4.1. Key market trends
4.4.2. Growth factors and opportunities
4.4.3. Market size and forecast

4.5. INFECTIOUS DISEASES

4.5.1. Key market trends
4.5.2. Growth factors and opportunities
4.5.3. Market size and forecast

4.6. NEUROLOGIC DISEASES

4.6.1. Key market trends
4.6.2. Growth factors and opportunities
4.6.3. Market size and forecast

4.7. OTHER RARE DISEASES

4.7.1. Key market trends
4.7.2. Growth factors and opportunities
4.7.3. Market size and forecast

CHAPTER 5 ORPHAN DRUGS MARKET, BY INDICATION

5.1. OVERVIEW

5.1.1. Market Size and Forecast

5.2. NON-HODGKINS LYMPHOMA

5.2.1. Market size and forecast

5.3. ACUTE MYELOID LEUKEMIA

5.3.1. Market size and forecast

5.4. CYSTIC FIBROSIS

5.4.1. Market size and forecast

5.5. GLIOMA

5.5.1. Market size and forecast

5.6. PANCREATIC CANCER

5.6.1. Market size and forecast

5.7. OVARIAN CANCER

5.7.1. Market size and forecast

5.8. MULTIPLE MYELOMA

5.8.1. Market size and forecast

5.9. DUCHENNE MUSCULAR DYSTROPHY

5.9.1. Market size and forecast

5.10. GRAFT VS. HOST DISEASE

5.10.1. Market size and forecast

5.11. RENAL CELL CARCINOMA

5.11.1. Market size and forecast

5.12. OTHERS

5.12.1. Market size and forecast

CHAPTER 6 ORPHAN DRUGS MARKET, BY GEOGRAPHY

6.1. OVERVIEW

6.1.1. Market size and forecast

6.2. NORTH AMERICA

6.2.1. Key market trends
6.2.2. Key growth factors and opportunities
6.2.3. Market size and forecast

6.2.3.1. U.S. market size and forecast
6.2.3.2. Canada market size and forecast
6.2.3.3. Mexico market size and forecast

6.3. EUROPE

6.3.1. Key market trends
6.3.2. Key growth factors and opportunities
6.3.3. Market size and forecast

6.3.3.1. Germany market size and forecast
6.3.3.2. UK market size and forecast
6.3.3.3. France market size and forecast
6.3.3.4. Italy market size and forecast
6.3.3.5. Spain market size and forecast
6.3.3.6. Rest of Europe market size and forecast

6.4. ASIA-PACIFIC

6.4.1. Key market trends
6.4.2. Key growth factors and opportunities
6.4.3. Market size and forecast

6.4.3.1. Japan market size and forecast
6.4.3.2. China market size and forecast
6.4.3.3. India market size and forecast
6.4.3.4. Australia market size and forecast
6.4.3.5. South Korea market size and forecast
6.4.3.6. Taiwan market size and forecast
6.4.3.7. Rest of Asia-Pacific market size and forecast

6.5. LAMEA

6.5.1. Key market trends
6.5.2. Key growth factors and opportunities
6.5.3. Market size and forecast

6.5.3.1. Brazil market size and forecast
6.5.3.2. Turkey market size and forecast
6.5.3.3. Saudi Arabia market size and forecast
6.5.3.4. South Africa market size and forecast
6.5.3.5. Rest of LAMEA market size and forecast

CHAPTER 7 COMPANY PROFILES

7.1. ABBVIE INC.

7.1.1. Company overview
7.1.2. Company snapshot
7.1.3. Operating business segments
7.1.4. Product portfolio
7.1.5. Business performance
7.1.6. Key strategic moves and developments

7.2. AEGERION PHARMACEUTICALS, INC. (NOVELION THERAPEUTICS INC.)

7.2.1. Company overview
7.2.2. Company snapshot
7.2.3. Operating business segments
7.2.4. Product portfolio
7.2.5. Business performance
7.2.6. Key strategic moves and developments

7.3. BRISTOL-MYERS SQUIBB COMPANY

7.3.1. Company overview
7.3.2. Company snapshot
7.3.3. Operating business segment
7.3.4. Product portfolio
7.3.5. Business performance
7.3.6. Key strategic moves and developments

7.4. CELGENE CORPORATION

7.4.1. Company overview
7.4.2. Company snapshot
7.4.3. Operating business segments
7.4.4. Product portfolio
7.4.5. Business performance
7.4.6. Key strategic moves and developments

7.5. F. HOFFMANN-LA ROCHE AG

7.5.1. Company overview
7.5.2. Company snapshot
7.5.3. Operating business segments
7.5.4. Product portfolio
7.5.5. Business performance
7.5.6. Key strategic moves and developments

7.6. GLAXOSMITHKLINE PLC

7.6.1. Company overview
7.6.2. Company snapshot
7.6.3. Operating business segments
7.6.4. Product portfolio
7.6.5. Business performance
7.6.6. Key strategic moves and developments

7.7. JOHNSON & JOHNSON

7.7.1. Company overview
7.7.2. Company snapshot
7.7.3. Operating business segments
7.7.4. Product portfolio
7.7.5. Business performance
7.7.6. Key strategic moves and developments

7.8. NOVARTIS AG

7.8.1. Company overview
7.8.2. Company snapshot
7.8.3. Operating business segments
7.8.4. Product portfolio
7.8.5. Business performance
7.8.6. Key strategic moves and developments

7.9. PFIZER INC.

7.9.1. Company overview
7.9.2. Company snapshot
7.9.3. Operating business segments
7.9.4. Product portfolio
7.9.5. Business performance
7.9.6. Key strategic moves and developments

7.10. SANOFI

7.10.1. Company overview
7.10.2. Company snapshot
7.10.3. Operating business segments
7.10.4. Product portfolio
7.10.5. Business performance
7.10.6. Key strategic moves and developments

LIST OF TABLES

TABLE 1. GLOBAL ORPHAN DRUGS MARKET, BY DISEASE TYPE, 2014-2022 ($MILLION)
TABLE 2. KEY ORPHAN THERAPEUTIC DRUGS FOR RARE FORMS OF ONCOLOGIC DISEASES
TABLE 3. ONCOLOGIC DISEASE ORPHAN DRUGS MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 4. KEY ORPHAN THERAPEUTIC DRUGS FOR RARE FORMS OF METABOLIC DISEASES
TABLE 5. METABOLIC DISEASE ORPHAN DRUGS MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 6. KEY ORPHAN THERAPEUTIC DRUGS FOR RARE FORMS OF HEMATOLOGIC AND IMMUNOLOGIC DISEASES
TABLE 7. HEMATOLOGIC AND IMMUNOLOGIC DISEASE ORPHAN DRUGS MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 8. KEY ORPHAN THERAPEUTIC DRUGS FOR RARE FORMS OF INFECTIOUS DISEASES
TABLE 9. INFECTIOUS DISEASE ORPHAN DRUGS MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 10. KEY ORPHAN THERAPEUTIC DRUGS FOR RARE FORMS OF NEUROLOGIC DISEASES
TABLE 11. NEUROLOGIC DISEASE ORPHAN DRUGS MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 12. OTHER RARE DISEASES ORPHAN DRUGS MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 13. GLOBAL ORPHAN DRUGS MARKET, BY INDICATION, 2014-2022 ($MILLION)
TABLE 14. NON-HODGKIN'S LYMPHOMA ORPHAN DRUGS MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 15. ACUTE MYELOID LEUKEMIA ORPHAN DRUGS MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 16. CYSTIC FIBROSIS ORPHAN DRUGS MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 17. GLIOMA ORPHAN DRUGS MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 18. PANCREATIC CANCER ORPHAN DRUGS MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 19. OVARIAN CANCER ORPHAN DRUGS MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 20. MULTIPLE MYELOMA ORPHAN DRUGS MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 21. DUCHENNE MUSCULAR DYSTROPHY ORPHAN DRUGS MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 22. GRAFT VS. HOST DISEASE ORPHAN DRUGS MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 23. RENAL CELL CARCINOMA ORPHAN DRUGS MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 24. OTHER INDICATIONS ORPHAN DRUGS MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 25. ORPHAN DRUGS MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 26. NORTH AMERICA ORPHAN DRUGS MARKET, BY COUNTRY, 2014-2022 ($MILLION)
TABLE 27. NORTH AMERICA ORPHAN DRUGS MARKET, BY DISEASE TYPE, 2014-2022 ($MILLION)
TABLE 28. NORTH AMERICA ORPHAN DRUGS MARKET, BY INDICATION, 2014-2022 ($MILLION)
TABLE 29. EUROPE ORPHAN DRUGS MARKET, BY COUNTRY, 2014-2022 ($MILLION)
TABLE 30. EUROPE ORPHAN DRUGS MARKET, BY DISEASE TYPE, 2014-2022 ($MILLION)
TABLE 31. EUROPE ORPHAN DRUGS MARKET, BY INDICATION, 2014-2022 ($MILLION)
TABLE 32. ASIA-PACIFIC ORPHAN DRUGS MARKET, BY COUNTRY, 2014-2022 ($MILLION)
TABLE 33. ASIA-PACIFIC ORPHAN DRUGS MARKET, BY DISEASE TYPE, 2014-2022 ($MILLION)
TABLE 34. ASIA-PACIFIC ORPHAN DRUGS MARKET, BY INDICATION, 2014-2022 ($MILLION)
TABLE 35. LAMEA ORPHAN DRUGS MARKET, BY COUNTRY, 2014-2022 ($MILLION)
TABLE 36. LAMEA ORPHAN DRUGS MARKET, BY DISEASE TYPE, 2014-2022 ($MILLION)
TABLE 37. LAMEA ORPHAN DRUGS MARKET, BY INDICATION, 2014-2022 ($MILLION)
TABLE 38. ABBVIE: COMPANY SNAPSHOT
TABLE 39. ABBVIE: OPERATING SEGMENTS
TABLE 40. ABBVIE: OPERATING SEGMENTS
TABLE 41. AEGERION PHARMACEUTICALS: COMPANY SNAPSHOT
TABLE 42. AEGERION PHARMACEUTICALS: OPERATING SEGMENTS
TABLE 43. AEGERION PHARMACEUTICALS: OPERATING SEGMENTS
TABLE 44. BRISTOL-MYERS SQUIBB: COMPANY SNAPSHOT
TABLE 45. BRISTOL-MYERS SQUIBB: OPERATING SEGMENTS
TABLE 46. BRISTOL-MYERS SQUIBB: PRODUCT PORTFOLIO
TABLE 47. CELGENE: COMPANY SNAPSHOT
TABLE 48. CELGENE: OPERATING SEGMENTS
TABLE 49. CELGENE: PRODUCT PORTFOLIO
TABLE 50. ROCHE: COMPANY SNAPSHOT
TABLE 51. ROCHE: OPERATING SEGMENT
TABLE 52. ROCHE: PRODUCT PORTFOLIO
TABLE 53. GSK: COMPANY SNAPSHOT
TABLE 54. GSK: OPERATING SEGMENTS
TABLE 55. GSK: PRODUCT PORTFOLIO
TABLE 56. J&J: COMPANY SNAPSHOT
TABLE 57. J&J: OPERATING SEGMENTS
TABLE 58. J&J: PRODUCT PORTFOLIO
TABLE 59. NOVARTIS: COMPANY SNAPSHOT
TABLE 60. NOVARTIS: OPERATING SEGMENTS
TABLE 61. NOVARTIS: PRODUCT PORTFOLIO
TABLE 62. PFIZER: COMPANY SNAPSHOT
TABLE 63. PFIZER: OPERATING SEGMENTS
TABLE 64. PFIZER: PRODUCT CATEGORY
TABLE 65. SANOFI: COMPANY SNAPSHOT
TABLE 66. SANOFI: OPERATING SEGMENTS
TABLE 67. SANOFI: PRODUCT PORTFOLIO

LIST OF FIGURES

FIGURE 1. SEGMENTATION SNAPSHOT: GLOBAL ORPHAN DRUGS MARKET, 2014-2022
FIGURE 2. GEOGRAPHY SNAPSHOT: GLOBAL ORPHAN DRUGS MARKET, 2014-2022
FIGURE 3. ORPHAN DRUGS MARKET: SEGMENTATION
FIGURE 4. TOP INVESTMENT POCKETS IN GLOBAL ORPHAN DRUGS MARKET
FIGURE 5. TOP WINNING STRATEGIES: TYPE AND COMPANY
FIGURE 6. TOP WINNING STRATEGIES: TYPE AND NATURE
FIGURE 7. BARGAINING POWER OF BUYERS
FIGURE 8. BARGAINING POWER OF SUPPLIERS
FIGURE 9. THREAT OF NEW ENTRANTS
FIGURE 10. THREAT OF SUBSTITUTION
FIGURE 11. COMPETITIVE RIVALRY
FIGURE 12. PATENT REGISTERED/APPROVED- BY YEAR
FIGURE 13. PATENT REGISTERED/APPROVED- BY REGION
FIGURE 14. PATENT REGISTERED/APPROVED- BY INDICATION
FIGURE 15. RESTRAINTS AND DRIVERS: GLOBAL ORPHAN DRUGS MARKET
FIGURE 16. COSTS PER YEAR ASSOCIATED WITH MOST EXPENSIVE ORPHAN DRUGS
FIGURE 17. ORPHAN DRUGS MARKET: DISEASE TYPE SEGMENTATION
FIGURE 18. CANCER: NUMBER OF DEATHS (UNIT) IN U.S., 2017 ESTIMATES
FIGURE 19. GLOBAL ORPHAN DRUGS MARKET:DISEASE CONDITION SEGMENTATION
FIGURE 20. U.S. ORPHAN DRUGS MARKET, 2014-2022 ($MILLION)
FIGURE 21. CANADA ORPHAN DRUGS MARKET, 2014-2022 ($MILLION)
FIGURE 22. MEXICO ORPHAN DRUGS MARKET, 2014-2022 ($MILLION)
FIGURE 23. GERMANY ORPHAN DRUGS MARKET, 2014-2022 ($MILLION)
FIGURE 24. UK ORPHAN DRUGS MARKET, 2014-2022 ($MILLION)
FIGURE 25. FRANCE ORPHAN DRUGS MARKET, 2014-2022 ($MILLION)
FIGURE 26. ITALY ORPHAN DRUGS MARKET, 2014-2022 ($MILLION)
FIGURE 27. SPAIN ORPHAN DRUGS MARKET, 2014-2022 ($MILLION)
FIGURE 28. REST OF EUROPE ORPHAN DRUGS MARKET, 2014-2022 ($MILLION)
FIGURE 29. JAPAN ORPHAN DRUGS MARKET, 2014-2022 ($MILLION)
FIGURE 30. CHINA ORPHAN DRUGS MARKET, 2014-2022 ($MILLION)
FIGURE 31. INDIA ORPHAN DRUGS MARKET, 2014-2022 ($MILLION)
FIGURE 32. AUSTRALIA ORPHAN DRUGS MARKET, 2014-2022 ($MILLION)
FIGURE 33. SOUTH KOREA ORPHAN DRUGS MARKET, 2014-2022 ($MILLION)
FIGURE 34. TAIWAN ORPHAN DRUGS MARKET, 2014-2022 ($MILLION)
FIGURE 35. REST OF ASIA-PACIFIC ORPHAN DRUGS MARKET, 2014-2022 ($MILLION)
FIGURE 36. BRAZIL ORPHAN DRUGS MARKET, 2014-2022 ($MILLION)
FIGURE 37. TURKEY ORPHAN DRUGS MARKET, 2014-2022 ($MILLION)
FIGURE 38. SAUDI ARABIA ORPHAN DRUGS MARKET, 2014-2022 ($MILLION)
FIGURE 39. SOUTH AFRICA ORPHAN DRUGS MARKET, 2014-2022 ($MILLION)
FIGURE 40. REST OF LAMEA ORPHAN DRUGS MARKET, 2014-2022 ($MILLION)
FIGURE 41. ABBVIE: REVENUE, 20142016 ($MILLION)
FIGURE 42. ABBVIE: REVENUE BY PRODUCT, 2016 (%)
FIGURE 43. ABBVIE: REVENUE BY GEOGRAPHY, 2016 (%)
FIGURE 44. AEGERION PHARMACEUTICALS: REVENUE, 20132015 ($MILLION)
FIGURE 45. AEGERION PHARMACEUTICALS: REVENUE BY PRODUCT, 2015 (%)
FIGURE 46. AEGERION PHARMACEUTICALS: REVENUE BY GEOGRAPHY, 2015 (%)
FIGURE 47. BRISTOL-MYERS SQUIBB: REVENUE, 20142016 ($MILLION)
FIGURE 48. BRISTOL-MYERS SQUIBB: REVENUE BY PRODUCTS, 2016 (%)
FIGURE 49. BRISTOL-MYERS SQUIBB: REVENUE BY GEOGRAPHY, 2016 (%)
FIGURE 50. CELGENE: REVENUE, 20142016 ($MILLION)
FIGURE 51. CELGENE: REVENUE BY PRODUCTS, 2016 (%)
FIGURE 52. CELGENE: REVENUE BY GEOGRAPHY, 2016 (%)
FIGURE 53. ROCHE: REVENUE, 20142016 ($MILLION)
FIGURE 54. ROCHE: REVENUE BY SEGMENT, 2016 (%)
FIGURE 55. ROCHE: REVENUE BY GEOGRAPHY, 2016 (%)
FIGURE 56. GSK: REVENUE, 20142016 ($MILLION)
FIGURE 57. GSK: REVENUE BY SEGMENT, 2016 (%)
FIGURE 58. GSK: REVENUE BY GEOGRAPHY, 2016 (%)
FIGURE 59. J&J: REVENUE, 20142016 ($MILLION)
FIGURE 60. J&J: REVENUE BY SEGMENT, 2016 (%)
FIGURE 61. J&J: REVENUE BY GEOGRAPHY, 2016 (%)
FIGURE 62. NOVARTIS: REVENUE, 20142016 ($MILLION)
FIGURE 63. NOVARTIS: REVENUE BY SEGMENT, 2016 ($MILLION)
FIGURE 64. NOVARTIS: REVENUE BY GEOGRAPHY, 2016 ($MILLION)
FIGURE 65. PFIZER: REVENUE, 20142016 ($MILLION)
FIGURE 66. PFIZER: REVENUE BY SEGMENT, 2016 ($MILLION)
FIGURE 67. PFIZER: REVENUE BY GEOGRAPHY, 2016 ($MILLION)
FIGURE 68. SANOFI: REVENUE, 20142016 ($MILLION)
FIGURE 69. SANOFI: REVENUE BY SEGMENT, 2016 ($MILLION)
FIGURE 70. SANOFI: REVENUE BY GEOGRAPHY, 2016 ($MILLION)

Enquiry Before Buy